AKT1 and breast carcinoma: Afuresertib is a potent protein kinase B (AKT) inhibitor that exhibits favorable tumor-suppressive effects on breast cancer cells by potently inhibiting the phosphatidylinositol 3‐kinase (PI3K)/AKT signaling pathway [38].